An affinity-based method for the purification of platelet factor 4 from outdated platelet concentrates

Goodarzi, Alireza; Yari, Fatemeh; Mohammadipour, Mahshid

doi:10.61186/rabms.9.3.123

Volume 9, Issue 3 (7-2023) Journal of Research in Applied and Basic Medical Sciences 2023, 9(3): 123-129 | Back to browse issues page

‎ 10.61186/rabms.9.3.123

Mendeley

Zotero

RefWorks

Goodarzi A, Yari F, Mohammadipour M. An affinity-based method for the purification of platelet factor 4 from outdated platelet concentrates. Journal of Research in Applied and Basic Medical Sciences 2023; 9 (3) :123-129
URL: http://ijrabms.umsu.ac.ir/article-1-270-en.html

An affinity-based method for the purification of platelet factor 4 from outdated platelet concentrates

Alireza Goodarzi

, Fatemeh Yari ^*

, Mahshid Mohammadipour

Professor of Medical Immunology, Iranian Blood Transfusion Research Center, Tehran, Iran , yarii.fatemeh@gmail.com

Abstract: (866 Views)

Background & Aims: Platelet factor 4 (PF4) is considered as a chemokine mainly strode in the granules of platelets. Its important role in heparin-induced thrombocytopenia (HIT) was the basis of many investigations about this chemokine. High affinity to heparin was used to extract of PF4 from platelet concentrates (PCs). Despite many advantages of recombinant PF4 (rPF4), some researchers prefer to purify rich proteins of platelets from outdated PCs mainly because of cost effectiveness. The main aim of this study was introducing a home-made method to purify PF4 from PCs in blood banks.
Materials & Methods: In this experimental study, we presented a customized procedure based on immunoaffinity chromatography to isolate PF4 that may be useful for laboratory access of PCs from blood bank centers. Briefly, platelet lysate (PL) was extracted from PCs by freeze/thaw cycles and then treated with anti-PF4 antibody to elute PF4 extract in the final product. Data were analyzed by SPSS software (version 26). Student t-test was used to compare the results. A probability of < 0.05 was accepted as significant statistically.
Results: Our experiments showed that immunoaffinity chromatography might be considered as an alternative source to provide PF4 particularly in view of cost effectiveness.
Conclusion: PF4 is one of the most bulk growth factors stored in platelets. It has the versatile applications both in diagnosis of HIT and in the study of platelet biology. A home-made protocol presented in this investigation can be helpful to obtain PF4 from blood bank in a reasonable scale.

Keywords: Immunoaffinity Chromatography, Platelet concentrate, Platelet factor 4, Purification

Full-Text [PDF 404 kb] (464 Downloads) | | Full-Text (HTML) (256 Views)

Type of Study: orginal article | Subject: Hematology

References

1. Deuel TF, Keim PS, Farmer M, Heinrikson RL. Amino acid sequence of human platelet factor 4. Proc Natl Acad Sci. 1977;74(6):2256-8. [DOI:10.1073/pnas.74.6.2256] [PMID] []

2. Vandercappellen J, Van Damme J, Struyf S. The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine Growth Factor Rev. 2011;22(1):1-18. [DOI:10.1016/j.cytogfr.2010.10.011] [PMID]

3. Levine S, Wohl H. Human platelet factor 4: Purification and characterization by affinity chromatography. Purification of human platelet factor 4. J Biol Chem. 1976;251(2):324-8. https://doi.org/10.1016/S0021-9258(17)33882-6 [DOI:10.1016/s0021-9258(17)33882-6] [PMID]

4. Wu V-Y, Walz DA, McCoy LE. Purification and characterization of human and bovine platelet factor 4. Prep Biochem. 1977;7(6):479-93. [DOI:10.1080/00327487708065515] [PMID]

5. Huang SS, Huang J, Deuel T. Proteoglycan carrier of human platelet factor 4. Isolation and characterization. J Biol Chem. 1982;257(19):11546-50. https://doi.org/10.1016/S0021-9258(18)33796-7 [DOI:10.1016/s0021-9258(18)33796-7] [PMID]

6. Huynh A, Arnold DM, Moore JC, Smith JW, Kelton JG, Nazy I. Development of a high-yield expression and purification system for platelet factor 4. Platelets. 2018;29(3):249-56. [DOI:10.1080/09537104.2017.1378808] [PMID]

7. Van Raemdonck K, Berghmans N, Vanheule V, Bugatti A, Proost P, Opdenakker G, et al. Angiostatic, tumor inflammatory and anti-tumor effects of CXCL447-70 and CXCL4L147-70 in an EGF-dependent breast cancer model. Oncotarget. 2014;5(21):10916. [DOI:10.18632/oncotarget.2538] [PMID] []

8. Wang Z, Huang H. Platelet factor-4 (CXCL4/PF-4): an angiostatic chemokine for cancer therapy. Cancer Lett. 2013;331(2):147-53. [DOI:10.1016/j.canlet.2013.01.006] [PMID]

9. Cervi D, Yip T-T, Bhattacharya N, Podust VN, Peterson J, Abou-Slaybi A, et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood. 2008;111(3):1201-7. [DOI:10.1182/blood-2007-04-084798] [PMID]

10. Kowalska MA, Rauova L, Poncz M. Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. Thromb Res. 2010;125(4):292-6. [DOI:10.1016/j.thromres.2009.11.023] [PMID]

11. Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood. 2006;107(6):2346-53. [DOI:10.1182/blood-2005-08-3122] [PMID] []

12. Morgan F, Chesterman C, McGready J, Begg G. Studies on the chemistry of human platelet factor 4. Haemostasis. 1977;6(1):53-8. [DOI:10.1159/000214165] [PMID]

13. Medici I, Di Martino A, Cella G, Callegaro L, Prosdocimi M. Improved method for purification of human platelet factor 4 by affinity and ion-exchange chromatography. Thromb Res. 1989;54(4):277-87. [DOI:10.1016/0049-3848(89)90086-8] [PMID]

14. Barone AD, Ghrayeb J, Hammerling U, Zucker MB, Thorbecke GJ. The expression in Escherichia coli of recombinant human platelet factor 4, a protein with immunoregulatory activity. J Biol Chem. 1988;263(18):8710-5. https://doi.org/10.1016/S0021-9258(18)68363-2 [DOI:10.1016/s0021-9258(18)68363-2] [PMID]

15. Zucker MB, Katz IR. Platelet factor 4: production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med. 1991;198(2):693-702. [DOI:10.3181/00379727-198-43309] [PMID]

16. Goodarzi A, Yari F, Mohammadipour M, Deyhim MR, Timori Naghadeh H. Capability of Platelet Factor 4 to Induce Apoptosis in the Cancerous Cell Lines in Vitro. Intl J Med Lab. 2018;5(3):195-207. 17. Shimizu T, Ishikawa Y, Morishima Y, Fukuda T, Kato K. Platelet factor 4 release from the platelets stored in platelet concentrates. Transfusion. 1985;25(5):420-3. [DOI:10.1046/j.1537-2995.1985.25586020114.x] [PMID]

17. Lippi G, Favaloro EJ. Recombinant platelet factor 4: a therapeutic, anti-neoplastic chimera? Semin Thromb Hemost. 2010;36(5):558-69. [DOI:10.1055/s-0030-1255450] [PMID]

18. Ginsberg MH, Taylor L, Painter RG. The mechanism of thrombin-induced platelet factor 4 secretion. Blood. 1980;55(4):661-8. https://doi.org/10.1182/blood.V55.4.661.661 [DOI:10.1182/blood.v55.4.661.661] [PMID]

19. Schallmoser K, Strunk D. Preparation of pooled human platelet lysate (pHPL) as an efficient supplement for animal serum-free human stem cell cultures. JoVE. 2009(32):e1523. [DOI:10.3791/1523-v] [PMID] []